NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. (NRXP) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
nrxp · stock forecast · 5 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 5 Wall Street analysts in the past 3 months
Buy
5 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$2.00
Consensus
$2.00
-53.8% upside
Low
$2.00
Median: $2 · Last Close: $4.33
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
BullAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $4.55 | ↑ 5.00% |
1-day model range: $4.48–$4.61. Peak: $4.61 (+5.00%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $3 | -31.8% |
| 2028 | $2 | -42.6% |
| 2029 | $2 | -47.1% |
| 2030 | $2 | -49.2% |
| 2031 | — | -50.3% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · NRXP · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-05 | D. Boral Capital | Maintains | Buy→Buy |
| 2026-04-27 | Ascendiant Capital | Maintains | Buy→Buy |
| 2026-04-27 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-04-23 | D. Boral Capital | Maintains | Buy→Buy |
| 2026-04-20 | D. Boral Capital | Maintains | Buy→Buy |
| 2026-03-24 | BTIG | Maintains | Buy→Buy |
| 2026-03-24 | D. Boral Capital | Maintains | Buy→Buy |
| 2026-03-17 | D. Boral Capital | Maintains | Buy→Buy |
| 2026-03-16 | D. Boral Capital | Maintains | Buy→Buy |
| 2026-03-09 | D. Boral Capital | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on NRx Pharmaceuticals, Inc. (NRXP) stock. Of the recent 60 rating actions, 0 were upgrades and 0 were downgrades. 5 analysts currently cover NRXP.
Analyst Recommendation Trends
NRXP analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 4 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$21M
↓ 95.9% YoY
Revenue Next Year
$204M
↑ 886.7% YoY
EPS This Year
$-0.17
EPS Next Year
$0.23
↓ 239.3% YoY
EPS ForecastReported vs Estimated
Analysts forecast NRXP EPS of $-0.17 for the current fiscal year, based on estimates from 2 analysts. The NRXP revenue forecast is $21M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The NRXP stock forecast is supported by two independent data sources: analyst consensus ratings from 5 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus NRXP price target is $2.00 (-53.8% upside), with an analyst consensus of Buy.
The NRXP short-term stock prediction for tomorrow is $4.55 (+5.00%). The NRXP stock price prediction for 2027 estimates an average of $3. The NRXP stock prediction for 2030 projects a range of $2–$3.
NRx Pharmaceuticals, Inc. trades on NASDAQ under the ticker NRXP. The NRXP stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
NRXP forecast · 8 questionsAccording to 5 Wall Street analysts, the average 12-month NRXP price target is $2.00, with a high forecast of $2.00 and a low of $2.00. The median price target is shown in the chart above when available. This implies -53.8% potential upside from the current price of $4.33.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.